Zhang Hui, Wang Aifei, Li Guangfei, Zhai Qiaocheng, Huang Zhengyun, Wang Xiao, Cao Zihou, Liu Lulin, Liu Gongwen, Chen Bin, Zhu Keyu, Xu Ying, Xu Youjia
Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China; Department of Orthopaedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China; Osteoporosis Clinical Center, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China; Osteoporosis Clinical Center, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China; Institute of Osteoporosis Diagnosis and Treatments of Soochow University, Suzhou, 215004, China.
Free Radic Biol Med. 2023 Mar;198:123-136. doi: 10.1016/j.freeradbiomed.2023.01.026. Epub 2023 Feb 3.
Excess iron accumulation is a risk factor for osteopenia and osteoporosis, and ferroptosis is becoming well understood as iron-dependent form of cell death resulting from lipid peroxide accumulation. However, any pathological impacts of ferroptosis on osteoporosis remain unknown. Here, we show that ferroptosis is involved in excess-iron-induced bone loss and demonstrate that osteoporotic mice and humans have elevated skeletal accumulation of the NADPH oxidase 4 (NOX4) enzyme. Mechanistically, we found that the NOX4 locus contains iron-response element-like (IRE-like) sequences that are normally bound (and repressed) by the iron regulatory protein 1 (IRP1) protein. Binding with iron induces dissociation of IRP1 from the IRE-like sequences and thereby activates NOX4 transcription. Elevated NOX4 increases lipid peroxide accumulation and causes obvious dysregulation of mitochondrial morphology and function in osteoblasts. Excitingly, the osteoporotic bone loss which we initially observed in an excessive-iron accumulating mouse line (Hepc1) was blocked upon treatment with the ferroptosis-inhibitor ferrostatin-1 (Ferr-1) and with the iron chelator deferoxamine (DFO), suggesting a potential therapeutic strategy for preventing osteoporotic bone loss based on disruption of ferroptosis.
铁过量蓄积是骨质减少和骨质疏松的一个风险因素,而铁死亡作为一种因脂质过氧化物蓄积导致的铁依赖性细胞死亡形式正逐渐为人所熟知。然而,铁死亡对骨质疏松的任何病理影响仍不清楚。在此,我们表明铁死亡参与了铁过量诱导的骨质流失,并证明骨质疏松小鼠和人类骨骼中烟酰胺腺嘌呤二核苷酸磷酸氧化酶4(NOX4)的蓄积增加。从机制上讲,我们发现NOX4基因座包含铁反应元件样(IRE样)序列,这些序列通常由铁调节蛋白1(IRP1)结合(并抑制)。与铁结合会诱导IRP1从IRE样序列上解离,从而激活NOX4转录。NOX4升高会增加脂质过氧化物的蓄积,并导致成骨细胞线粒体形态和功能明显失调。令人兴奋的是,我们最初在铁过量蓄积小鼠品系(Hepc1)中观察到的骨质疏松性骨质流失在用铁死亡抑制剂铁抑素-1(Ferr-1)和铁螯合剂去铁胺(DFO)治疗后被阻断,这提示了一种基于破坏铁死亡来预防骨质疏松性骨质流失的潜在治疗策略。